Abstract: A number of single domain antibodies (sdAb, also known as nanobodies or VHH) were developed that bind nucleocapsid protein of the SARS-CoV-2 virus. They are useful for detecting the virus and could also find application in therapeutics.
Type:
Grant
Filed:
October 28, 2021
Date of Patent:
August 29, 2023
Assignee:
The Government of the United States of America, as represented by the Secretary of the Navy
Inventors:
Ellen R. Goldman, George P. Anderson, Jinny L. Liu, Thomas J. Esparza
Abstract: An isolated monoclonal antibody that specifically binds human Siglec15, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same.
Abstract: Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.
Type:
Grant
Filed:
April 2, 2020
Date of Patent:
August 22, 2023
Inventors:
Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
July 11, 2023
Assignee:
MACROGENICS, INC.
Inventors:
Ezio Bonvini, Paul A. Moore, Jonathan C. Li, Leslie S. Johnson, Kalpana Shah
Abstract: The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and show the same specificity as the parental antibody.
Type:
Grant
Filed:
January 18, 2017
Date of Patent:
June 13, 2023
Assignees:
NanoCruise Pharmaceutical Ltd., Board of Regents of The University
of Texas System
Abstract: The present invention provides methods for treating or preventing cancer by administering an anticancer agent and an antigen-binding molecule comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor complex-binding domain. The present invention also provides pharmaceutical compositions for treating or preventing cancer, each comprising a combination of the anticancer agent and the antigen-binding molecule.
Abstract: The present invention relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides directed to at least two targets. In another embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides and an enhancer moiety.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
May 23, 2023
Assignee:
iCell Gene Therapeutics Inc.
Inventors:
Yupo Ma, Kevin Pinz, Xun Jiang, Masayuki Wada, Kevin Chen
Abstract: The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.
Type:
Grant
Filed:
September 25, 2019
Date of Patent:
May 2, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Sandra Grau-Richards, Christian Klein, Pablo Umaña, Maria Amann, Laurene Pousse
Abstract: CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
Type:
Grant
Filed:
March 3, 2020
Date of Patent:
May 2, 2023
Assignee:
MacroGenics, Inc.
Inventors:
Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
April 25, 2023
Assignee:
AMGEN INC.
Inventors:
Wei Yan, Martin J. Pentony, Luis G. Borges, Mark L. Michaels
Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.
Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Type:
Grant
Filed:
June 20, 2017
Date of Patent:
March 28, 2023
Assignee:
TeneoBio, Inc.
Inventors:
Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.
Abstract: Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
Type:
Grant
Filed:
April 22, 2019
Date of Patent:
February 28, 2023
Assignee:
NantCell, Inc.
Inventors:
Shahrooz Rabizadeh, Patrick Soon-Shiong
Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.
Type:
Grant
Filed:
September 12, 2018
Date of Patent:
February 14, 2023
Assignee:
Novartis AG
Inventors:
Leonardo Borras, Tea Gunde, David Urech
Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
February 7, 2023
Assignee:
PRECISION BIOLOGICS, INC.
Inventors:
Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having a particular set of mutations at the interface of the CH1 and CL domains, the mutations preventing heavy chain/light chain mispairing.
Type:
Grant
Filed:
March 27, 2018
Date of Patent:
January 24, 2023
Assignee:
BIOMUNEX PHARMACEUTICALS
Inventors:
Eugene Zhukovsky, Olivier Leger, Richard J. Morse
Abstract: The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
January 17, 2023
Assignee:
LamKap Bio beta Ltd.
Inventors:
Vanessa Buatois, Stefano Majocchi, Klaus Strein